Jade Biosciences (JBIO) Q4 2025 earnings summary

Executive summary

• Advanced three pipeline candidates: JADE101 (Phase 1 ongoing, Phase 2 planned), JADE201 (Phase 1 planned), and JADE301 (Phase 1 planned for 2027).

• Ended 2025 with $336 million in cash, cash equivalents, and investments, providing runway into H1 2028.

• Completed two private placements in Q4 2025, raising $180 million from healthcare investors.

Financial highlights

• Cash, cash equivalents, and investments totaled $336.2 million as of December 31, 2025, up from $69.4 million at end of 2024.

• R&D expenses were $28.5 million in Q4 2025 (up from $17.6 million in Q4 2024) and $93.1 million for full year 2025 (up from $31.2 million for 2024 partial year).

• G&A expenses were $6.4 million in Q4 2025 (up from $2.4 million in Q4 2024) and $20.4 million for full year 2025 (up from $4.3 million for 2024 partial year).

• Net loss was $31.9 million in Q4 2025 (vs. $30.1 million in Q4 2024) and $127.4 million for full year 2025 (vs. $47.0 million for 2024 partial year).

• Interest income for 2025 was $7.8 million; comprehensive loss for 2025 was $127.3 million.

Outlook and guidance

• JADE101 Phase 1 interim data expected Q2 2026; Phase 2 in IgA nephropathy to begin mid-2026 with preliminary data in 2027.

• JADE201 first-in-human trial in rheumatoid arthritis to start Q2 2026; interim data in 2027.

• JADE301 Phase 1 trial expected to commence in H1 2027; further details to be disclosed in H2 2026.

• Cash runway expected to fund operations into H1 2028.